Transforming Beta-Thalassemia Care: A Detailed Exploration of CRISPR Therapeutics AG's CASGEVY and how it compares against other approved products

Executed on:Apr 23, 2024 9:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Children’s Hospital of Orange CountyBoard certified in pediatrics and pediatric hematology-oncology
Specializes in all aspects of hematology with emphasis in hemoglobinopathies, including beta thalassemia and sickle cell disease. Manages 70 patients with SCD and 35 with beta thalassemia.
Established a comprehensive red cell clinic at CHOC to treat patients with red cell disorders

Interview Goal

This project is dedicated to examining the potential impact of CRISPR Therapeutics AG's CASGEVY (CTX001), an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy, in the treatment of Beta-thalassemia. The focus will be on its ability to reduce transfusion dependency, enhance patient quality of life, and its potential as a groundbreaking cure for this genetic disorder.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.